SS Innovations Reports Revenue of $14.5M, Up 79.0% Year Over Year
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 10 2026
0mins
Should l Buy SSII?
Reports revenue $14.5M vs. $8.1M last year. SSi Mantra surgical robotic system installations totaled 40, up 81.8% from 22 installations in the fourth quarter of 2024 and up 48.1% from 27 installations in the third quarter of 2025. Sudhir Srivastava, CEO, commented, "In the fourth quarter of 2025, we achieved strong growth in SSi Mantra installations, procedures and revenues, capping off a successful year for SS Innovations. Among our accomplishments in 2025, we gained significant share of the surgical robotics market in India, expanded into new global geographies, and progressed along the regulatory pathways required for entering the United States and European Union markets. We also continued to pioneer robotic telesurgery, attaining multiple new procedure milestones and unveiling cutting-edge innovations such as the Tele Surgeon Console and MantraM mobile robotic telesurgery unit. Finally, the uplisting of our shares to Nasdaq has enhanced market awareness of our growth story and expanded our audience of potential investors. After quarter-end we completed a private placement of common stock, which brings us new long-term oriented institutional investors and approximately $18.6 million of gross proceeds aimed to fuel SS Innovations' growth in 2026 and beyond. Significant insider participation in this financing reflects our strong confidence in SS Innovations' future. We will continue to invest in enhancements to our advanced, cost-effective SSi Mantra surgical robotic system and expand our capacity to lead the vast Indian market, penetrate underserved global geographies, and prepare for our entry into the United States and European Union. We anticipate that the U.S. Food and Drug Administration will complete its review of our 510(k) premarket notification for the SSi Mantra by mid-2026. We also continue along the pathway towards a European Union CE marking certification for the SSi Mantra, which we believe we can also obtain this year. In conclusion, we expect continuing strong growth in 2026 as we deploy the SSi Mantra in existing and new markets, increasing access to world-class surgical robotic care."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SSII?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SSII
About SSII
SS Innovations International, Inc. is a developer of surgical robotic technologies. The Company’s product range includes its proprietary SSi Mantra surgical robotic system and its comprehensive suite of SSi Mudra surgical instruments, which support a variety of surgical procedures including robotic cardiac surgery. The SSi Mantra Surgical Robotic System is designed to enable surgeons to perform a wide range of surgical procedures including cardiovascular, thoracic, head and neck, gynecological, urological, cancer and general surgeries. The SSi Mantra 3 is comprised of components, such as Surgeon Console, Patient-Side Robotic Arm Carts, and Vision Cart. Its instruments under development include NADI-Automated Coronary Anastomotic Connector, SSi Multi-Fire Clip Applier, SSi Ultrasonic Surgical Device, SSi Maya-XR Pre-Operative Simulator, SSi Holographic Anatomy, SSi Yog-Tele Proctor, SSi Chitrasa-Advanced DICOM Viewer and SSi Mixed Reality Headset.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
SS Innovations Unveils Cutting-Edge Surgical Robotics at SMRSC 2026
- Technology Showcase: At the Global Multi-Specialty Robotic Surgery Conference in New Delhi, SS Innovations unveiled several cutting-edge surgical robotic technologies, including the SSi Vimana Aero drone system and the SSi Avtara humanoid surgical platform, aimed at enhancing global healthcare accessibility and affordability.
- Battlefield Medical Innovation: The SSi Vimana Aero drone system is designed to provide surgical care directly to injured soldiers in combat zones, deploying via heavy-lift drones with two miniature robotic arms that have seven degrees of freedom, significantly reducing the critical time from injury to medical evacuation.
- Mobile Operating Room Revolution: The SSi Operion mobile operating room is designed for seamless deployment across hospitals, remote locations, and disaster zones, featuring a zero-footprint architecture that allows 360-degree clinician access, which is expected to transform traditional operating room operations and enhance service flexibility.
- Clinical Validation Progress: The new single-arm robotic endoscopy and ultrasound assist carts are undergoing early clinical validation in India, aimed at providing stable and precise positioning of endoscopic and ultrasound instruments within clinical environments, ensuring safe interaction with both patients and operators.
See More
SS Innovations Hosts Global Robotic Surgery Conference
- Conference Expansion: SS Innovations is hosting the Global Multi-Specialty Robotic Surgery Conference from April 9-11, 2026, in New Delhi, with expected attendance surpassing 1,400, reflecting growing interest and demand for robotic surgical technologies.
- Live Surgery Demonstrations: Over 20 live telesurgeries will be performed during the conference using the SSi Mantra surgical robotic system, led by top experts, aimed at showcasing critical technologies such as connectivity and cybersecurity, thereby promoting industry standardization.
- Innovative Technology Showcase: The SSi Vimana Aero drone system will be featured at the conference, designed to provide rapid robotic surgical care to injured soldiers in combat zones, highlighting its significance in emergency medical response and battlefield care.
- Future Operating Room Concept: Project Operion will present an interactive window into the future of surgical robotics, emphasizing the need for mobile high-tech surgical infrastructure, aiming to enhance accessibility and efficiency of healthcare through telesurgery integration.
See More
SS Innovations Secures Regulatory Approvals in Multiple Countries
- Global Market Expansion: SS Innovations' SSi Mantra surgical robotic system has received regulatory approvals in Colombia, Oman, Sri Lanka, and Kenya, marking a significant step in the company's global expansion and is expected to enhance its competitiveness in these underpenetrated markets.
- Significant Technological Advantages: With its advanced technology, cost advantages, and user-friendliness, the SSi Mantra is anticipated to attract more healthcare institutions, thereby driving sales growth and increasing market share globally.
- Surgery Volume Growth: As of December 31, 2025, the cumulative installed base of the SSi Mantra reached 168 units across ten countries, with a total of 7,885 surgeries performed, including 390 cardiac procedures and 121 pediatric surgeries, demonstrating its widespread application in surgical fields.
- Positive Future Outlook: The company anticipates that the FDA will complete its review of the SSi Mantra's 510(k) premarket notification by mid-2026, while also actively pursuing CE marking certification in the European market, further strengthening its competitive position globally.
See More
SS Innovations International Inc. Secures Regulatory Approval for SSI Mantra in Colombia, Oman, Sri Lanka, and Kenya
Regulatory Approval: Innovations International has received regulatory approval for its Ssimantra train in multiple countries including Colombia, Oman, Sri Lanka, and Kenya.
Market Expansion: This approval marks a significant step in expanding the company's market presence in these regions, potentially enhancing transportation options.
See More
SS Innovations International Reports Significant Growth in FY 2025
- Earnings Highlights: SS Innovations International reported a Q4 GAAP EPS of -$0.01 with revenues of $14.5 million and a gross margin of 43.9%, down from 48.9% in Q4 2024, indicating profitability pressures amid revenue growth.
- Annual Performance Surge: For FY 2025, total revenue surged 105.7% to $42.5 million, with gross margin improving from 40.9% in 2024 to 46.0%, showcasing significant achievements in cost control and sales growth.
- Substantial Gross Profit Increase: The gross profit for FY 2025 rose 131.2% to $19.5 million, up from $8.5 million in 2024, reflecting strong performance in product sales and market demand.
- Robotic System Installations Growth: Installations of the SSi Mantra surgical robotic system totaled 103, a 119.1% increase from 47 installations in 2024, demonstrating rapid expansion and increasing market acceptance in the medical device sector.
See More
SS Innovations Reports Strong Financial Growth in 2025
- Significant Revenue Growth: In Q4 2025, SS Innovations reported a 79.1% year-over-year revenue increase to $14.5 million, indicating strong demand for surgical robotics and expected to enhance market share further.
- Gross Margin Fluctuation: Although gross margin decreased from 48.9% to 43.9%, gross profit rose by 60.7% to $6.4 million, reflecting both challenges and opportunities in cost management and sales growth.
- Surge in Installations: The number of SSi Mantra surgical robotic system installations reached 40 in Q4 2025, an 81.8% increase, which not only strengthens the company's competitive position but also lays a foundation for future revenue growth.
- Funding to Support Future Growth: The company completed a private placement raising approximately $18.6 million in early 2026, attracting long-term investors, which is expected to fuel technological innovation and market expansion, further solidifying its leadership in the global surgical robotics sector.
See More
SS Innovations Unveils Cutting-Edge Surgical Robotics at SMRSC 2026
- Technology Showcase: At the Global Multi-Specialty Robotic Surgery Conference in New Delhi, SS Innovations unveiled several cutting-edge surgical robotic technologies, including the SSi Vimana Aero drone system and the SSi Avtara humanoid surgical platform, aimed at enhancing global healthcare accessibility and affordability.
- Battlefield Medical Innovation: The SSi Vimana Aero drone system is designed to provide surgical care directly to injured soldiers in combat zones, deploying via heavy-lift drones with two miniature robotic arms that have seven degrees of freedom, significantly reducing the critical time from injury to medical evacuation.
- Mobile Operating Room Revolution: The SSi Operion mobile operating room is designed for seamless deployment across hospitals, remote locations, and disaster zones, featuring a zero-footprint architecture that allows 360-degree clinician access, which is expected to transform traditional operating room operations and enhance service flexibility.
- Clinical Validation Progress: The new single-arm robotic endoscopy and ultrasound assist carts are undergoing early clinical validation in India, aimed at providing stable and precise positioning of endoscopic and ultrasound instruments within clinical environments, ensuring safe interaction with both patients and operators.
See More
SS Innovations Hosts Global Robotic Surgery Conference
- Conference Expansion: SS Innovations is hosting the Global Multi-Specialty Robotic Surgery Conference from April 9-11, 2026, in New Delhi, with expected attendance surpassing 1,400, reflecting growing interest and demand for robotic surgical technologies.
- Live Surgery Demonstrations: Over 20 live telesurgeries will be performed during the conference using the SSi Mantra surgical robotic system, led by top experts, aimed at showcasing critical technologies such as connectivity and cybersecurity, thereby promoting industry standardization.
- Innovative Technology Showcase: The SSi Vimana Aero drone system will be featured at the conference, designed to provide rapid robotic surgical care to injured soldiers in combat zones, highlighting its significance in emergency medical response and battlefield care.
- Future Operating Room Concept: Project Operion will present an interactive window into the future of surgical robotics, emphasizing the need for mobile high-tech surgical infrastructure, aiming to enhance accessibility and efficiency of healthcare through telesurgery integration.
See More
SS Innovations Secures Regulatory Approvals in Multiple Countries
- Global Market Expansion: SS Innovations' SSi Mantra surgical robotic system has received regulatory approvals in Colombia, Oman, Sri Lanka, and Kenya, marking a significant step in the company's global expansion and is expected to enhance its competitiveness in these underpenetrated markets.
- Significant Technological Advantages: With its advanced technology, cost advantages, and user-friendliness, the SSi Mantra is anticipated to attract more healthcare institutions, thereby driving sales growth and increasing market share globally.
- Surgery Volume Growth: As of December 31, 2025, the cumulative installed base of the SSi Mantra reached 168 units across ten countries, with a total of 7,885 surgeries performed, including 390 cardiac procedures and 121 pediatric surgeries, demonstrating its widespread application in surgical fields.
- Positive Future Outlook: The company anticipates that the FDA will complete its review of the SSi Mantra's 510(k) premarket notification by mid-2026, while also actively pursuing CE marking certification in the European market, further strengthening its competitive position globally.
See More
SS Innovations International Inc. Secures Regulatory Approval for SSI Mantra in Colombia, Oman, Sri Lanka, and Kenya
Regulatory Approval: Innovations International has received regulatory approval for its Ssimantra train in multiple countries including Colombia, Oman, Sri Lanka, and Kenya.
Market Expansion: This approval marks a significant step in expanding the company's market presence in these regions, potentially enhancing transportation options.
See More
SS Innovations International Reports Significant Growth in FY 2025
- Earnings Highlights: SS Innovations International reported a Q4 GAAP EPS of -$0.01 with revenues of $14.5 million and a gross margin of 43.9%, down from 48.9% in Q4 2024, indicating profitability pressures amid revenue growth.
- Annual Performance Surge: For FY 2025, total revenue surged 105.7% to $42.5 million, with gross margin improving from 40.9% in 2024 to 46.0%, showcasing significant achievements in cost control and sales growth.
- Substantial Gross Profit Increase: The gross profit for FY 2025 rose 131.2% to $19.5 million, up from $8.5 million in 2024, reflecting strong performance in product sales and market demand.
- Robotic System Installations Growth: Installations of the SSi Mantra surgical robotic system totaled 103, a 119.1% increase from 47 installations in 2024, demonstrating rapid expansion and increasing market acceptance in the medical device sector.
See More
SS Innovations Reports Strong Financial Growth in 2025
- Significant Revenue Growth: In Q4 2025, SS Innovations reported a 79.1% year-over-year revenue increase to $14.5 million, indicating strong demand for surgical robotics and expected to enhance market share further.
- Gross Margin Fluctuation: Although gross margin decreased from 48.9% to 43.9%, gross profit rose by 60.7% to $6.4 million, reflecting both challenges and opportunities in cost management and sales growth.
- Surge in Installations: The number of SSi Mantra surgical robotic system installations reached 40 in Q4 2025, an 81.8% increase, which not only strengthens the company's competitive position but also lays a foundation for future revenue growth.
- Funding to Support Future Growth: The company completed a private placement raising approximately $18.6 million in early 2026, attracting long-term investors, which is expected to fuel technological innovation and market expansion, further solidifying its leadership in the global surgical robotics sector.
See More
